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osting by EAbstract Three Schiff bases in two different concentrations were evaluated for their anti-tumor
activity against Ehrlich ascites carcinoma (EAC) bearing Swiss albino mice. The in vivo anti-tumor
potency of Schiff bases was assessed by measuring the increase in mean survival time of the drug
treated over untreated control mice and treated standard (cisplatin) mice. Their toxicity was
assessed in vivo in normal, standard, and EAC-bearing mice by measuring the drug-induced changes
in biochemical as well as hematological parameters. The histopathology studies to assess the toxic-
ity of these compounds on vital organs also have been studied. Among the three Schiff bases stud-
ied, 4-({[3-(4-ﬂuorophenyl)-1H-pyrazol-4-yl]methylene}amino)-5-[(2-methylphenoxy)methyl]-1,2,4-
triazole-3-thiol (SB-3) at an optimal dose of 100 mg/kg body weight was found to enhance the mean
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26 D. Sunil et al.bearing mice were found to be signiﬁcantly restored towards normal after treatment with SB-3
100 mg/kg body weight of mice. The ALP and SGOT values were found to approach the normal
range. A:G ratios also did not deviate from normal on treatment with SB-3. The histopathology
studies revealed only mild hepatotoxicity and nephrotoxicity when compared to the normal and
standard. The splenic cellularity also did not show much variation from normal. SB-3 at a prime
dose of 100 mg has shown promising anticancer activity in vivo against EAC when compared to
standard drug with minimum toxic effects.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Cancer or malignant neoplasm is a class of diseases in which a
group of cells display uncontrolled growth, invasion and even
sometimes metastasis (De Vita et al., 2005; Thomas and Vinay,
2007). It continues as a serious public health problem through-
out the world as the most feared diagnosis. It is the second lead-
ing cause of human death after cardiovascular diseases in
developing as well as in developed countries (Babasaheb et al.,
2010). Currently, the treatment for cancer primarily includes
surgery and chemotherapy, but the curative effects of the exist-
ing chemotherapeutic drugs are not good enough and they have
plentiful side effects. The development of more effective drugs
for treating patients with cancer has been a main attempt over
the past 50 years. In recent years, various 1,2,4-triazole deriva-
tives have been found to be associated with anticancer (Al-Soud
et al., 2006; Holla et al., 2002; Ikizler et al., 2003) properties.
AK-2123 (Sanazol), a nitrotriazole hypoxic cell sensitizer has
supposedly improved results in head and neck cancers, uterine
cervical cancers and other solid tumors when added to radical
radiotherapy (Dobrowsky et al., 2005). Non-steroidal aroma-
tase inhibitors obtained from triazole derivatives are used in
the treatment of breast cancer (Robert et al., 2004). Current lit-
erature shows 1,2-pyrazole derivatives to possess various bio-
logical activities (Mathew et al., 2007; Konagai et al., 2002). It
is also observed that incorporation of aryl substituents and hal-
ogen atoms into the heterocyclic ring systems enhances the bio-
logical activities considerably (Padmavathi et al., 2009). Several
Schiff bases were reported to possess potential anticancer prop-
erties (Holla et al., 2003). In view of the wide spectrum ofmedic-
inal applications, especially anticancer properties of various
triazole derivatives and in continuation of our research on bio-
logically active new molecules, we hereby report the anticancer
activity of three Schiff bases in vivo.
In vitro screening in hepatic carcinoma cell lines (Hep G2)
using MTT assay, revealed the cytotoxicity of the Schiff bases
(Dhanya et al., in press). Their in vivo anti-tumor potency was
assessed in Ehrlich ascites carcinoma (EAC) cells by assessing
the increase in median survival times and body weights of drug
treated (T) over untreated control (C) and standard (S) mice.
Results showed that the survival time of treated mice was
markedly increased by SB-3 at an optimal dose of 100 mg/kg
body weight. Its toxic effects was studied in vivo in normal
and EAC-bearing mice by measuring drug-induced changes
in hematological, biochemical parameters as well as organ tox-
icities on day 15 following drug treatment. The hematological
and biochemical parameters were mostly within normal limit.
Histology of liver and kidney revealed mild abnormality upon
treatment with SB-3 (100 mg/kg body weight). Minor splenic
toxicity in treated groups SB-3 (100 mg/kg body weight) simi-
lar to standard group was observed.2. Materials and methods
All the chemicals used in the present study were from Sigma–
Aldrich, USA. Adult female swiss albino mice of 6–8 weeks old
weighing 25–30 g, inbred at Central Animal Research Facility,
Manipal University, Karnataka, India were used throughout
the study. Animals were housed in polypropylene cages con-
taining sterile paddy husk as bedding material under hygienic
conditions with a maximum of four animals in a cage. They
were maintained under controlled conditions (10:14 h light:-
dark), temperature (23 ± 3 C). Animals were fed on auto-
claved standard mice food pellets (Hindustan Lever) and
water ad libitum. The animal experiments were performed
according to the rules and regulations of the Institutional Ani-
mal Ethics Committee (IAEC).
Three Schiff bases, 4-({[3-(4-chlorophenyl)-1H-pyrazol-
4-yl]methylene}amino)-5-[(4-methylphenoxy)methyl]-1,2,4-tri-
azole-3-thiol (SB-1), 4-({[3-(4-ﬂuorophenyl)-1H-pyrazol-
4-yl]methylene}amino)-5-[(4-methylphenoxy)methyl]-1,2,4-tri-
azole-3-thiol (SB-2) and 4-({[3-(4-ﬂuorophenyl)-1H-pyrazol-
4-yl]methylene}amino)-5-[(2-methylphenoxy)methyl]-1,2,4-tri-
azole-3-thiol (SB-3) were prepared by the method as described
in the literature (Kalluraya et al., 2009; Dhanya et al., in press).
Their structures were conﬁrmed by IR, NMR and mass spec-
tral studies. IR spectra of Schiff bases showed an absorption
band at 1600–1610 cm1 characteristic of –C‚N– group in
the molecule. Also the absence of carbonyl stretching band
at around 1700 cm1 clearly indicated amino condensation
and hence the formation of Schiff bases. The 1H NMR spec-
trum of Schiff base showed a singlet at d 9.95 due to the pres-
ence of proton in –N‚CH group in the molecule, conﬁrming
the formation of Schiff bases. Mass spectrum of the three
Schiff bases showed molecular ion peaks which were in agree-
ment with their molecular formula. The elemental analysis was
also carried out. The purity of the compounds was checked
using LC–MS technique. The structure of the Schiff bases
are given in Fig. 1.
2.1. In vivo anticancer studies
The drug solutions were prepared daily just prior to the injec-
tion by suspending them in 0.25% CMC (carboxy methyl cel-
lulose) and was administered intraperitoneally. The dose of the
standard drug, cisplatin was selected as 3.5 mg/kg mice body
weight. This was calculated from the human dose using an
appropriate conversion factor (Sathisha et al., 2008).
Ehrlich ascites carcinoma cells to induce cancer in animal
model (mice) were obtained from Amala Cancer Research
Center, Amala Nagar, Kerala, India. The cells were main-
tained as ascites tumor in swiss albino mice by intraperitoneal
inoculation of 1 · 106 viable cells (Sathisha et al., 2008; Devi
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Figure 1 Structure of Schiff bases.
In vivo anticancer and histopathology studies of Schiff bases on Ehrlich ascitic carcinoma cells 27et al., 1998). Acute toxicity studies were carried out as per the
OECD guidelines, 2001. For determining the maximum toler-
ated dose of the Schiff bases, the standard protocol was fol-
lowed by administering the Schiff bases to normal swiss
albino mice at the dose range up to 2000 mg/kg body weight
after depriving them of food for 18 h. Animals were observed
for any symptoms of toxicity continuously for 4 h, then after
24 h and ﬁnally the number of survivors were noted after a per-
iod of 72 h. Depending on the results obtained, the therapeutic
doses for further studies were selected (1/10th to 1/20th of the
maximum tolerated dose).
For the in vivo assay, nine groups were formed. Each group
comprised of 12 female swiss albino mice. Formed groups are
as follows:
 Group 1: The normal mice.
 Group 2: The EAC-bearing mice (Control).
 Group 3: The EAC-bearing mice on a single dose of cis-
platin (Standard).
 Groups 4–9 represented the study group, treated with Schiff
bases as depicted below:
– Group 4: SB-1 (50 mg/kg).
– Group 5: SB-1 (100 mg/kg).
– Group 6: SB-2 (50 mg/kg).
– Group 7: SB-2 (150 mg/kg).
– Group 8: SB-3 (50 mg/kg).
– Group 9: SB-3 (100 mg/kg).The ascitic carcinoma bearing donor mice was taken 15 days
after tumor transplantation. The ascitic ﬂuid was drawn
using an 18-gauge needle into a sterile syringe. A small
amount was tested for microbial contamination. Tumor via-
bility was determined by Trypan blue exclusion test and cells
were counted using haemocytometer. The ascitic ﬂuid was
suitably diluted in normal saline to get a concentration of
10 · 106 cells/mL of tumor cell suspension. From this stock
suspension, 0.25 mL (2.5 million cells/mice) was injected
intraperitoneally to normal mice in order to obtain ascitic
tumor (day 0). Cisplatin (single dose) was given intraperito-
neally to the standard group on day 1. The three Schiff bases
in two different concentrations were administered on days 3,
5, 7, 10, 12 and 14 (6 doses) intraperitoneally. The control
group was treated with the vehicle (0.25% CMC). On day
15, from each group six mice were sacriﬁced for hematolog-
ical, biochemical and histopathological studies. The remain-ing six animals from each group were monitored daily for
30 days and mortality was recorded to calculate the mean
survival time.
2.1.1. Mean survival time and increase in lifespan (% ILS)
(Sathisha et al., 2008)
Total number of days an animal survived from the day of tu-
mor inoculation was counted. Subsequently mean survival
time (MST) for each group was calculated. Survival time for
treated group was compared with that of control group using
the following calculation:
Increase of life span ðILSÞ
¼ MST of treated groupMST of control group
MST of control group
 
 100
where MST ¼
P
survival time ðdaysÞ of each mice in a group
Total number of mice
.
2.1.2. Body weight (Eckchardt et al., 1982)
Body weights of all animals were measured on days 0, 3, 5, 7,
10, 12 and 14. The percentage increase in weight was calculated
as per the following equation:
% increase in weight
¼ Animal weight on respective dayAnimal weight on day 0
Animal weight on day 0
 
 1002.2. In vivo toxicological studies
On day 15, blood samples from six animals in each group were
taken in microfuge tubes containing EDTA for hematological
studies and the serum was collected for biochemical studies.
The animals were then sacriﬁced by cervical dislocation,
dissection was done and the liver, kidney and spleen were
removed for histopathology studies.
2.2.1. Hematological parameters (Mukherjee et al., 2007)
To study the hematological changes associated with Schiff
base administration, four parameters – (a) hemoglobin count
(b) erythrocyte count, (c) leukocyte count and (d) differential
count were determined in peripheral blood of mice. The blood
was withdrawn from retro-orbital plexus on day 15 for the
study. The values were then compared with the normal and
standard values.
2.2.2. Biochemical parameters (Pain et al., 2003)
Numerous laboratory investigations have been proposed in the
assessment of liver dysfunction. For evaluating drug induced
hepatotoxicity, liver function tests were done and values
obtained for treated groups were compared with the normal
value. From among the host of liver function tests, the follow-
ing battery of blood tests namely bilirubin, SGOT, SGPT,
ALP and protein levels were carried out.
2.3. Histopathology studies (Roy et al., 1981; Hassan et al.,
2009)
The animals were sacriﬁced by cervical dislocation. The liver,
kidneys and spleen were removed and stored in neutral forma-
28 D. Sunil et al.lin and histopathology studies were conducted. These were
processed by standard methods to prepare slides of tissues
by hematoxylin and eosin staining. The slides were viewed
under light microscope. Drug induced hepatotoxicity, nephro-
toxicity and spleen toxicity studies were performed
sequentially.
2.4. Statistical analysis
The statistical analyses were performed by one-way ANOVA,
followed by Tukey’s post hoc test using GraphPad Prism 5.02.
The results were expressed as the mean ± SEM. Differences
were considered signiﬁcant p< 0.05.3. Results and discussion
Cisplatin (3.5 mg/kg, i.p. single dose), signiﬁcantly enhanced
MST of EAC infected mice. Both SB-1 and SB-3 in both con-Survival proportio
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Figure 2 Effect of Schiff bases on the Kaplan Meier’s estimate of sur
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Figure 3 Effect of Schiff bases on body weight changes in EAC inocu
compared to control and bP< 0.05 compared to standard.centrations were found to increase the survival time of animals.
However, SB-3 at an optimal dose of 100 mg/kg showed
remarkable enhancement in the survival time of mice. It in-
creased the mean survival time by 24%. SB-2 in both concen-
trations was found to be inactive. The detailed data showing
the mean survival time is shown in Fig. 2.
Substantial gain in body weight was observed in control
mice with a maximum gain of 36.12%. In the case of SB-3
(100 mg/kg) treated mice, gain in body weight was only
11.11% indicative of its efﬁciency in bringing down the pro-
gression of cancer. The graph depicting the body weight
changes of animals is shown in Fig. 3.
Literature survey reveals that progression of tumor was
accompanied by the following hematological changes com-
pared to normal gradual decrease in hemoglobin content,
erythrocyte count and gradual increase in leukocytes which
was observed in control mice. The RBC count was almost re-
stored back to normal range on treatment with SB-3 (100 mg/
kg). It could also improve the RBC count, but not as efﬁcientlyns
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Figure 4 Effect of Schiff bases on RBC count in EAC challenged mice.
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Figure 5 Effect of Schiff bases on WBC count in EAC induced mice. aP< 0.05 compared to normal, bP< 0.05 compared to control
and cP< 0.05 compared to standard.
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Figure 6 Effect of Schiff bases on hemoglobin count in EAC inoculated mice. aP< 0.05 compared to normal, bP< 0.05 compared to
control and cP< 0.05 compared to standard.
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mal range in the SB-3 (100 mg/kg) treated groups. SB-3 at
an optimal dose of 100 mg/kg could bring down the WBC le-
vel, but not as efﬁciently as cisplatin. The detailed data ob-
tained for each hematological parameter is given in Figs. 4–
6. SB-3 (100 mg/kg) could bring down the count by 22% com-
pared to control.
It is well known that there are signiﬁcant elevations in the
levels of ALP (alkaline phosphatases) in case of chronic liver
problems. The ALP values were in normal range in SB-3
(100 mg/kg) treated group which is depicted in Fig. 7. In-
creases in both transaminases are found in liver diseases, with
SGPT (Serum glutamic pyruvic transaminase) much higher
than SGOT (Serum glutamic oxaloacetic transaminase). Veryhigh values are usually obtained in toxic hepatitis. The SGPT
and SGOT values remained in the normal range in SB-3
(100 mg/kg) treated group, suggestive of its efﬁciency with less
toxic effects when compared with the standard as seen in
Fig. 8. Plasma proteins yield most useful information in
chronic liver diseases. Liver is the site of albumin synthesis
and also possibly of some a and b globulins. Albumin (A) is
grossly decreased and the globulins (G) often increased, so that
A:G is reversed, which are characteristically seen in advanced
liver diseases. In the case of SB-3 (100 mg/kg) treated mice, the
protein levels did not vary signiﬁcantly from normal. Serum
bilirubin is also indicative of hepatotoxicity. The total bilirubin
levels were also in the normal range in SB-3 (100 mg/kg) trea-
ted mice as shown in Fig. 9.
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Figure 7 Effect of Schiff bases on transaminases and ALP in EAC challenged mice. aP< 0.05 compared to normal and bP< 0.05
compared to control.
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Figure 8 Effect of Schiff bases on protein content in EAC induced mice. aP< 0.05 compared to normal and bP< 0.05 compared to
control.
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Figure 9 Effect of Schiff bases on Bilirubin count in EAC induced mice. aP< 0.05 compared to normal and bP< 0.05 compared to
control.
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Figure 10 Histopathology of liver (40·). Animals were sacriﬁced on day 15 and histopathology of liver was studied for signs of
hepatotoxicity. The histology of liver of standard group showed cellular inﬁltration, congestion and mild central vein dilatation. SB-3
(50 mg/kg) treated group showed only mild central vein dilation suggesting less hepatotoxicity compared to control and standard.
Figure 11 Histopathology of kidney (40·). Animals were sacriﬁced on day 15 and histopathology of kidney was studied for signs of
nephrotoxicity. The standard showed signs of nephrotoxicity due to glomerular inﬁltration. The SB-3 (100 mg/kg) treated group also
showed mild glomerular inﬁltration. There were no signs of tubular necrosis, casts and glomerular congestion, which was indicative of
only mild nephrotoxicity with SB-3 (100 mg/kg).
In vivo anticancer and histopathology studies of Schiff bases on Ehrlich ascitic carcinoma cells 31
Figure 12 Histopathology of spleen (40·). Animals were sacriﬁced on day 15 and tissue sections of spleen were studied for signs of spleen
toxicity. Mild loss in spleen architecture is observed in SB-3 (100 mg/kg) and cisplatin treated mice spleen.
32 D. Sunil et al.The histopathology studies also revealed the relatively less
toxic nature of SB-3 (100 mg/kg) as compared to control and
standard group when viewed under light microscope of magni-
ﬁcation 40·. The liver is known to accumulate signiﬁcant
amounts of cisplatin, second to kidney. The histology studies
of liver of standard group showed cellular inﬁltration (inﬂam-
mation), congestion and mild central vein dilatation as seen in
Fig. 10. Whereas the SB-3 (100 mg/kg) treated group showed
only mild central vein dilation suggesting less hepatotoxicity
compared to standard group. The histopathology of the kid-
ney tissues of normal, control, standard and SB-3 (100 mg/
kg) treated mice are shown in Fig. 11. The control group
showed some cellular inﬁltration, while the standard group
showed signs of nephrotoxicity due to cellular and glomerular
inﬁltration. The SB-3 (100 mg/kg) treated group also showed
mild glomerular inﬁltration. There were no signs of tubular
necrosis, casts and glomerular congestion, which were indica-
tive of only mild nephrotoxicity, with SB-3 (100 mg/kg). The
standard group showed loss of splenic architecture and conges-
tion as depicted in Fig. 12. The treated group also showed mild
loss of splenic architecture but congestion was not observed
indicating lower splenic toxicity due to treatment with SB-3
(100 mg/kg).
4. Conclusions
In the light of the above observations, it can be concluded that
SB-3, at a dose of 100 mg/kg, optimally inhibits the growth of
EAC cells in vivo. This is evident from the reduced tumor
weight and enhanced life span of that study group. The treat-
ment with SB-3 (100 mg/kg) restored the deviated hematolog-
ical and biochemical parameters to the normal range. It is aneffective antineoplastic agent with comparatively less toxic ef-
fects. It is necessary that the anti-tumor activity of this Schiff
base should be carried out against other tumor cell lines which
may bring promising results in cancer chemotherapy.Acknowledgements
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